Michael Severino, AbbVie president
September 29, 2021 07:24 AM EDTUpdated October 1, 11:43 AM
Pharma
FDA+

Ab­b­Vie clos­es in on Bio­haven with new mi­graine pre­ven­tion OK for oral CGRP drug

Amber Tong

You can now add an­oth­er hefty phar­ma play­er to the com­mer­cial bat­tle for mi­graine pre­ven­tion.

Ab­b­Vie has land­ed an ap­proval for Qulip­ta, the oral CGRP …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times